Mechanism of Action
Selective ghrelin receptor (GHSR) agonist. Stimulates GH release from the pituitary with high selectivity — unlike earlier GHRPs (GHRP-2, GHRP-6), ipamorelin does not significantly elevate cortisol or prolactin at standard doses. The combination with CJC-1295 targets both the GHRH receptor and the GHSR simultaneously, producing synergistic GH release.
Ester Profile
Pentapeptide. Injectable. Short half-life of approximately 2 hours requires 2-3 daily injections for sustained GH elevation.
How It's Used in Fitness
Ipamorelin is the preferred GHRP for performance use precisely because it stimulates GH release with minimal effect on cortisol and prolactin, side effects that plagued earlier GHRPs. It is used for recovery enhancement, sleep quality improvement, and the body composition effects of elevated GH. Some athletes use it specifically before sleep to amplify the natural GH pulse that occurs during deep sleep, using the compound to augment rather than override natural GH secretion patterns. It is also used in injury recovery protocols alongside peptides like BPC-157 and TB-500 for a comprehensive tissue repair approach.
Stacking Context
Ipamorelin is almost always combined with CJC-1295 in performance protocols because the synergistic effect of stimulating both the GHRH and ghrelin receptors simultaneously produces substantially greater GH release than either compound alone. This pairing is the standard approach to peptide-based GH optimization in performance settings. Ipamorelin also appears in comprehensive recovery stacks alongside BPC-157 and TB-500 where each compound contributes to tissue repair through different mechanisms. It is rarely used with MK-677 because both compounds stimulate GH through the ghrelin receptor and the combined effect does not produce proportional synergy.
Medical Use
- Phase II trials for post-operative ileus
- Investigated for GH deficiency and anti-aging
- No approved therapeutic use
Side Effects
- Water retention — GH-mediated
- Headache and flushing — post-injection
- Increased appetite — mild ghrelin agonism
- Joint swelling — GH-related
- Insulin sensitivity changes with chronic use
- Fatigue reported
What Actually Goes Wrong
Ipamorelin's favorable side effect profile relative to other GHRPs does not mean it is consequence-free. The downstream effects of elevated GH and IGF-1, including insulin resistance and the theoretical proliferative risk, apply regardless of how the GH elevation is achieved. The short half-life of approximately two hours means that producing meaningful GH elevation throughout a day requires multiple injections, which increases the cumulative injection site exposure and the logistical burden. Research chemical quality variability is the same issue as with all compounds in this category.
Detection Window
WADA prohibits all GHRH and GH secretagogues. Detection methodology evolving.
Ipamorelin is as close to a clean GH secretagogue as the current research chemical market offers. That is a meaningful distinction within the category. It does not change the fact that you are using a compound with no approved human use and limited long-term human data to chronically manipulate a hormonal axis. If the goal is better sleep and recovery, the baseline variables of sleep hygiene, training load management, and nutrition adequacy deserve genuine assessment before adding any pharmaceutical intervention.